Human medicines European public assessment report (EPAR): Exjade, deferasirox, Date of authorisation: 28/08/2006, Revision: 57, Status: Authorised

Human medicines European public assessment report (EPAR): Dasatinib Accord Healthcare, dasatinib, Date of authorisation: 26/07/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Clopidogrel Zentiva (previously Clopidogrel Winthrop), clopidogrel, Date of authorisation: 15/07/2008, Revision: 33, Status: Authorised

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 26-29 January 2026

Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Date of authorisation: 06/11/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Yuvanci, macitentan,tadalafil, Date of authorisation: 27/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Lyxumia, lixisenatide, Date of authorisation: 31/01/2013, Revision: 21, Status: Withdrawn

Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 20, Status: Authorised

Committee for Advanced Therapies (CAT): 3-5 December 2025, European Medicines Agency, Amsterdam, the Netherlands, from 3 December 2025 to 5 December 2025